Compared to control group was administered placebo what was the result of Microencapsulated sodium butyrate (MSB) 300 mg daily on the number of abdominal ultrasound examinations performed for suspected diverticulitis and subsequent number of diverticulitis diagnosed based on abdominal US?
The number of diverticulitis clinical symptom occurrences during 12 months of observation was 2 (6.67 %) in the MSB group and was significantly lower (p = 0.0425) than the clinical symptoms of diverticulitis reported in the control group (7 occurrences, 31.8 %).